11.78
-0.29(-2.40%)
Currency In USD
| Previous Close | 12.07 |
| Open | 11.94 |
| Day High | 12.05 |
| Day Low | 11.67 |
| 52-Week High | 13.2 |
| 52-Week Low | 5.64 |
| Volume | 1.35M |
| Average Volume | 2.6M |
| Market Cap | 1.21B |
| PE | -7.75 |
| EPS | -1.52 |
| Moving Average 50 Days | 10.07 |
| Moving Average 200 Days | 7.91 |
| Change | -0.29 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $501.28 as of February 21, 2026 at a share price of $11.78. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $613.54 as of February 21, 2026 at a share price of $11.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
GlobeNewswire Inc.
Jan 11, 2026 10:00 PM GMT
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Mor
Day One Completes Acquisition of Mersana Therapeutics
GlobeNewswire Inc.
Jan 06, 2026 2:02 PM GMT
Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma (ACC)BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals